溶瘤病毒治疗作为免疫疗法。
Oncolytic virotherapy as immunotherapy.
机构信息
The Institute of Cancer Research, London, UK.
Mayo Clinic, Rochester, MN, USA.
出版信息
Science. 2021 Dec 10;374(6573):1325-1326. doi: 10.1126/science.abk3436. Epub 2021 Dec 9.
Abstract
Recognizing immune responses to oncolytic virotherapy opens the way for new combinations.
摘要
识别针对溶瘤病毒治疗的免疫反应为新的联合治疗开辟了道路。
相似文献
1
Oncolytic virotherapy as immunotherapy.
Science. 2021 Dec 10;374(6573):1325-1326. doi: 10.1126/science.abk3436. Epub 2021 Dec 9.
2
Development of oncolytic virotherapy: from genetic modification to combination therapy.
Front Med. 2020 Apr;14(2):160-184. doi: 10.1007/s11684-020-0750-4. Epub 2020 Mar 7.
3
From virotherapy to oncolytic immunotherapy: where are we now?
Curr Opin Virol. 2015 Aug;13:93-100. doi: 10.1016/j.coviro.2015.06.005. Epub 2015 Jun 26.
4
Integrating oncolytic viruses in combination cancer immunotherapy.
Nat Rev Immunol. 2018 Aug;18(8):498-513. doi: 10.1038/s41577-018-0014-6.
5
Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection.
Curr Opin Virol. 2015 Aug;13:25-32. doi: 10.1016/j.coviro.2015.03.015. Epub 2015 Apr 4.
6
Oncolytic Immunotherapy.
Surg Oncol Clin N Am. 2019 Jul;28(3):419-430. doi: 10.1016/j.soc.2019.02.007. Epub 2019 Apr 5.
7
Virotherapy--cancer targeted pharmacology.
Drug Discov Today. 2012 Mar;17(5-6):215-20. doi: 10.1016/j.drudis.2011.12.011. Epub 2011 Dec 16.
8
Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.
J Immunother Cancer. 2021 Apr;9(4). doi: 10.1136/jitc-2020-002086.
9
Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.
J Cell Physiol. 2019 Jun;234(6):8636-8646. doi: 10.1002/jcp.27850. Epub 2018 Dec 4.
10
Role of NK cells in immunotherapy and virotherapy of solid tumors.
Immunotherapy. 2015;7(8):861-82. doi: 10.2217/imt.15.53. Epub 2015 Aug 28.
引用本文的文献
1
The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.
J Hematol Oncol. 2025 Sep 2;18(1):84. doi: 10.1186/s13045-025-01732-z.
2
Oncolytic herpes simplex virus reprograms cancer-associated fibroblasts to enhance antitumor immunity in pancreatic cancer.
Mol Ther Oncol. 2025 Jul 16;33(3):201021. doi: 10.1016/j.omton.2025.201021. eCollection 2025 Sep 18.
3
Eliciting antitumor immunity via therapeutic cancer vaccines.
Cell Mol Immunol. 2025 Jul 9. doi: 10.1038/s41423-025-01316-4.
4
Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interaction.
Nat Commun. 2025 Jul 3;16(1):6136. doi: 10.1038/s41467-025-61439-0.
5
Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors.
J Immunother Cancer. 2025 Jun 5;13(6):e011517. doi: 10.1136/jitc-2025-011517.
6
Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack.
Immunotherapy. 2025 Jun;17(8):585-594. doi: 10.1080/1750743X.2025.2513853. Epub 2025 Jun 6.
7
Oligodendroglioma: Advances in Molecular Mechanisms and Immunotherapeutic Strategies.
Biomedicines. 2025 May 7;13(5):1133. doi: 10.3390/biomedicines13051133.
8
Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities.
J Immunother Cancer. 2025 May 19;13(5):e010570. doi: 10.1136/jitc-2024-010570.
9
Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer.
Biomedicines. 2025 Apr 5;13(4):882. doi: 10.3390/biomedicines13040882.
10
Viral expression of NE/PPE enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting TAM M1 polarization to reverse insufficient effector memory/effector CD8 T cell infiltration.
J Exp Clin Cancer Res. 2025 Mar 14;44(1):97. doi: 10.1186/s13046-025-03358-y.
本文引用的文献
1
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
Lancet Oncol. 2021 Aug;22(8):1103-1114. doi: 10.1016/S1470-2045(21)00245-X. Epub 2021 Jun 29.
2
Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
N Engl J Med. 2021 Apr 29;384(17):1613-1622. doi: 10.1056/NEJMoa2024947. Epub 2021 Apr 10.
3
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
JAMA Oncol. 2020 Dec 1;6(12):1939-1946. doi: 10.1001/jamaoncol.2020.3161.
4
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).
Oncoimmunology. 2019 Jun 3;8(8):1615817. doi: 10.1080/2162402X.2019.1615817. eCollection 2019.
5
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17.
6
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
7
Lung Cancer with a High Tumor Mutational Burden.
N Engl J Med. 2018 Sep 13;379(11):1093-1094. doi: 10.1056/NEJMc1808566.
8
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
Sci Transl Med. 2018 Jan 3;10(422). doi: 10.1126/scitranslmed.aam7577.
9
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
J Clin Oncol. 2018 Jun 10;36(17):1658-1667. doi: 10.1200/JCO.2017.73.7379. Epub 2017 Oct 5.
10
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.
J Immunother Cancer. 2017 Sep 19;5(1):71. doi: 10.1186/s40425-017-0277-7.
Zotero 插件